Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hims & Hers Health ( (HIMS) ) just unveiled an announcement.
On September 28, 2025, Hims & Hers Health, Inc. announced that its Chief Operating Officer, Nader Kabbani, will transition to an advisory role effective November 2, 2025, providing strategic guidance until July 2026. Mike Chi, currently the Chief Commercial Officer, will assume the role of Chief Operating Officer, consolidating operations, marketing, product, and commercial functions. Chi, who joined the company in April 2021, brings over 20 years of experience in consumer internet and has previously held senior marketing roles at Zola, INTERMIX, and Gilt Groupe. The company’s Compensation Committee will review Chi’s compensation in light of his new responsibilities.
The most recent analyst rating on (HIMS) stock is a Sell with a $28.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.
Spark’s Take on HIMS Stock
According to Spark, TipRanks’ AI Analyst, HIMS is a Neutral.
Hims & Hers Health’s overall score is driven by strong financial performance and positive earnings call sentiment, indicating growth potential. However, high leverage, cash flow concerns, and a high P/E ratio suggest caution. The company’s strategic expansions and technological advancements are promising, but operational challenges and valuation concerns temper the outlook.
To see Spark’s full report on HIMS stock, click here.
More about Hims & Hers Health
Average Trading Volume: 29,889,926
Technical Sentiment Signal: Buy
Current Market Cap: $12.73B
See more data about HIMS stock on TipRanks’ Stock Analysis page.